# ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse

> **NCT07379203** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Wits Health Consortium (Pty) Ltd** · enrollment: 130 (estimated)

## Conditions studied

- Cytomegalovirus (CMV) Infection

## Interventions

- **DRUG:** Valganciclovir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07379203
- **Lead sponsor:** Wits Health Consortium (Pty) Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2027-02-28
- **Final completion:** 2027-06-30
- **Target enrollment:** 130 (ESTIMATED)
- **Last updated:** 2026-01-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07379203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07379203, "ValgaNciclovIR for CMV Viraemia in AdvaNced HIV diseAse". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07379203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*